Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Hemiparkinsonism-Hemiatrophy Syndrome (HPHA): A Patient Guide

At a Glance

Hemiparkinsonism-hemiatrophy syndrome (HPHA) combines Parkinson-like movement symptoms with wasting or smaller size on the same side of the body. Its cause and course vary, so care is individualized with medication, physical therapy, and occupational therapy.

Hemiparkinsonism-Hemiatrophy Syndrome (HPHA) is a rare neurological condition that presents a unique puzzle for both patients and clinicians. It is defined by two primary features occurring on the same side of the body: parkinsonism—which includes symptoms like slowness of movement, muscle stiffness, and tremors—and hemiatrophy, which is the physical smaller size or wasting of the limbs, face, or trunk [1][2]. Unlike typical Parkinson’s disease, which is a widespread neurodegenerative process, HPHA has been hypothesized to be linked to a subtle, early-life injury to the brain or developmental differences that remain quiet for years before movement symptoms eventually emerge [3].

What is Known and What is Uncertain

  • Known: The name describes a pattern of symptoms, causes vary, and physical therapy helps manage asymmetry.
  • Uncertain: The natural history is not well defined because published evidence is sparse. Early injury is one hypothesis, not an established explanation for every patient, and the course cannot be predicted from the label alone.

The behavior of HPHA can be notably different from more common movement disorders, particularly in how it progresses. Because one proposed underlying issue is a “static” injury from early development or childhood rather than a rapidly advancing disease, in some reported cases the symptoms have remained confined to one side of the body for a decade or more [4]. However, this is an observed pattern in case reports, not a guarantee. The degree of physical asymmetry and the way the brain compensates mean that every patient’s experience is deeply individual [2].

Because HPHA is so rare, there are no “standard” treatment templates, making your relationship with your medical team vital. Management is a highly personalized process that often involves a combination of medication trials to address stiffness and slowness, alongside targeted physical and occupational therapy to manage the physical asymmetry [5][6]. While medications like levodopa may help some, the response is variable, and the focus remains on finding the specific tools—from exercise to environmental adjustments—that help you maintain your independence and quality of life. Understanding that your journey with HPHA is unique allows you to work with your specialists to build a care plan that is as specific as the condition itself [1][3].

Note: This guide is educational and does not replace an examination by a neurologist or other treating professional.

Common questions in this guide

What is hemiparkinsonism-hemiatrophy syndrome?
Hemiparkinsonism-hemiatrophy syndrome, or HPHA, is a rare neurological condition that combines Parkinson-like movement symptoms with smaller size or wasting on the same side of the body. Symptoms may include slowness, stiffness, tremor, and physical asymmetry.
What might cause HPHA?
The cause is not known for every person with HPHA. An early-life brain injury or developmental difference has been proposed, but this is a hypothesis and is not an established explanation for every case.
How is HPHA different from typical Parkinson’s disease?
HPHA includes Parkinson-like movement symptoms together with one-sided body asymmetry or wasting. Typical Parkinson’s disease is generally described as a widespread neurodegenerative process, while HPHA may be related to an early static brain injury or developmental difference; individual courses vary.
Can levodopa help with HPHA symptoms?
Levodopa may improve stiffness and slowness for some people with HPHA, but the response is variable. A neurologist may use medication trials and adjust the plan according to the person’s symptoms, function, and treatment goals.
What therapies can help people with HPHA?
Physical therapy can help address movement and body asymmetry, while occupational therapy can support daily activities and independence. Exercise and environmental adjustments may also be included in an individualized care plan.
Will HPHA get worse over time?
The long-term course of HPHA cannot be predicted from the diagnosis alone. In some reported cases, symptoms stayed limited to one side for a decade or longer, but that pattern is not a guarantee for every patient.

Get notified when new evidence is published on Hemiparkinsonism-hemiatrophy syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    Subcortical and brainstem hemiatrophy accompanied by iron deposition in a patient with hemiparkinsonism-hemiatrophy syndrome: a case report.

    Chung SJ

    BMC neurology 2021; (21(1)):51 doi:10.1186/s12883-021-02080-4.

    PMID: 33535984
  2. 2

    Neuropathologic findings in a patient with hemiparkinsonism and hemiatrophy syndrome.

    Nakamura M, Tsuge A, Miyake K, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2024; (44(6)):432-439 doi:10.1111/neup.12994.

    PMID: 38972833
  3. 3

    Hemiparkinsonism or Hemidystonia With Hemiatrophy Syndrome: A Case Series With Follow-Up.

    He C, Zhang P, Li Y, et al.

    Frontiers in neuroscience 2020; (14()):64 doi:10.3389/fnins.2020.00064.

    PMID: 32116511
  4. 4

    [Hemiparkinsonism-Hemiatrophy Syndrome with Hypoperfusion in Basal Ganglia: A Case Report].

    Ma B, Wang LH, Zhang YN

    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 2021; (52(3)):531-533 doi:10.12182/20210560106.

    PMID: 34018377
  5. 5

    Hemiparkinsonism-hemiatrophy syndrome.

    Ayromlou H, Najmi S, Arami MA

    Archives of Iranian medicine 2011; (14(2)):152-4 doi:011142/AIM.0017.

    PMID: 21361726
  6. 6

    Bidirectionality of the dentato-rubro-thalamo-cortical tract allows concurrent hypoperfusion in ipsilateral cerebellum and contralateral cerebral hemisphere: A case report.

    He HC, Hsu MC, Hsu CS, et al.

    Medicine 2018; (97(40)):e12590 doi:10.1097/MD.0000000000012590.

    PMID: 30290625

This HPHA guide is for informational purposes only and does not constitute medical advice. It cannot replace an examination or individualized guidance from a neurologist or other treating professional.